TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02927067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Participants will receive 400 mg of maribavir BID orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Participants will receive valganciclovir tablets orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo tablets matched to either maribavir or valganciclovir.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo tablets matched to either maribavir or valganciclovir.
Study: NCT04552262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: Single dose of 90 mg BAY2327949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo to BAY 2327949
Study: NCT04475809

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: group C
Description: laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group L
Description: laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group LR
Description: the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group LS
Description: the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
Study: NCT00988767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
Study: NCT02404532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIND1 System
Description: Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
Study: NCT04059809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
Study: NCT04111367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seraprevir
Description: Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seraprevir
Description: Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
Study: NCT01688648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Description: a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Description: a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
Study: NCT01379586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4053
Description: Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
Study: NCT01363895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous closure of LAA
Description: Percutaneous closure of LAA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation of AF
Description: Catheter ablation of AF
Study: NCT01464697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Description: 300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
Study: NCT03341403

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotical®/Bactecal®
Description: Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pills containing placebo
Study: NCT03016715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT02448823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass media and Stylish Events
Description: 1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mass Media
Description: 1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
Study: NCT03691558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western Diet
Description: total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
Study: NCT03123523

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography at T0

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography at T0

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise test

Intervention type: BIOLOGICAL
Intervention: Biological assays
Description: Creatinin, hematocrit and BNP assays

Intervention type: DEVICE
Intervention: MRI with contrast agent injection
Description: With injection of gadolinium

Intervention type: DEVICE
Intervention: MRI without contrast agent injection
Description: Without injection of gadolinium

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography at M24
Study: NCT02853019

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: subjective evaluation scales
Description: - clinical scales and subjective assessments of emotional and motivational stimuli
Study: NCT03183921

Intervention type: OTHER
Intervention: No intervention
Description: No Interventions
Study: NCT03531229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Lu AF76432 oral solution
Study: NCT02853019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: subjective evaluation scales
Description: - clinical scales and subjective assessments of emotional and motivational stimuli
Study: NCT03531229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF76432
Description: Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
Study: NCT02125760

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity IMT
Description: High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
Study: NCT03979261

Intervention type: DIAGNOSTIC_TEST
Intervention: evolution of sex ratio according to age
Description: Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
Study: NCT03808519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n3 PUFA-enriched fish oil
Description: 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Study: NCT03350477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02333929

Intervention type: DEVICE
Intervention: STA- Rivaroxaban Calibrator&Control
Description: One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)

Intervention type: DEVICE
Intervention: STA- Rivaroxaban Calibrator&Control
Description: One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
Study: NCT03808519

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Organic Sunflower Oil 5000mg per day
Study: NCT02333929

Intervention type: DEVICE
Intervention: STA- Rivaroxaban Calibrator&Control
Description: One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
Study: NCT00674934

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT00565500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: celecoxib capsules 200 mg bid for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: ibuprofen tablets 600 mg tid for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules tid for 1 week
Study: NCT00377299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active medication in all other physical aspects
Study: NCT03033108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily, tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily, tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat
Description: Once daily, tablet for oral administration
Study: NCT04317222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCRRT
Description: eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment
Study: NCT02482220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Study: NCT00693355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium butyrate
Description: sodium butyrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl
Study: NCT01656616

Intervention type: DRUG
Intervention: Cyanide antidote administration
Study: NCT02275572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention
Study: NCT01471574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Interferon alfa 2a
Description: Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
Study: NCT01795937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: once daily
Study: NCT02802865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01994499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videothoracoscopy drainage
Description: videothoracoscopy drainage of pleural effusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical drainage
Description: Medical pleural drainage
Study: NCT03923478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-M201
Description: Active Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Treatment
Study: NCT02616653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3-L4 location: Palpation method confirmed by US
Description: An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3-L4 location: Palpation method confirmed by US
Description: An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
Study: NCT00583479

Intervention type: OTHER
Group type: OTHER
Intervention: one injection into the celiac ganglion
Description: one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer

Intervention type: OTHER
Group type: OTHER
Intervention: two injections into the celiac ganglion
Description: two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
Study: NCT02060825

Intervention type: DEVICE
Intervention: Regional saturation monitor
Study: NCT00332371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPFA (Coupled Plasma Filtration Adsorption)
Description: CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter.
Study: NCT01371435

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT04540939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
Study: NCT03167619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: olaparib 300mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product in combination with Durvalumab
Description: olaparib 300mg twice daily plus intravenous durvalumab every 28 days
Study: NCT00390923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline + nicotine replacement therapy
Description: Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + nicotine replacement therapy
Description: Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.